Salivary, serum, and abomasal mucus IgA as an immune correlate of protection against Haemonchus contortus infection in naturally infected lambs

2022 ◽  
Author(s):  
Jordana Andrioli Salgado ◽  
Sthefany Kamile dos Santos ◽  
Jessea de Fátima França Biz ◽  
Matheus Borges de Carvalho ◽  
Fernanda Rigo ◽  
...  
Keyword(s):  
Haemonchus Contortus ◽  
Correlate Of Protection ◽  
Immune Correlate

scholarly journals Development and Validation of 13-plex Luminex-Based Assay for Measuring Human Serum Antibodies to Streptococcus pneumoniae Capsular Polysaccharides

mSphere ◽  
2018 ◽  
Vol 3 (4) ◽  
pp. e00128-18 ◽  
Author(s):  
Danka Pavliakova ◽  
Peter C. Giardina ◽  
Soraya Moghazeh ◽  
Shite Sebastian ◽  
Maya Koster ◽  
...  
Keyword(s):  
Human Serum ◽  
Lower Limit ◽  
Immunosorbent Assay ◽  
Enzyme Linked Immunosorbent Assay ◽  
Igg Antibodies ◽  
Igg Antibody ◽  
Correlate Of Protection ◽  
Immune Correlate ◽  
Relative Standard ◽  
Limit Of Quantitation

ABSTRACT A Luminex-based direct immunoassay (dLIA) platform has been developed to replace the standardized pneumococcal enzyme-linked immunosorbent assay platform. The multiplex dLIA simultaneously measures the concentration of serum immunoglobulin G (IgG) antibodies specific for pneumococcal capsular polysaccharide (PnPS) serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F. The assay uses poly-l-lysine (PLL)-conjugated PnPS, chemically coupled to spectrally distinct Luminex microspheres. Assay validation experiments were performed using residual human serum samples obtained from 13-valent pneumococcal conjugate vaccine (13vPnC) clinical studies. Assay results are expressed as IgG antibody concentrations in micrograms per milliliter using the international reference serum, 007sp. The lower limit of quantitation (LLOQ) for all serotypes covered in the 13-plex dLIA fell within the range of 0.002 to 0.038 µg/ml serum IgG. The difference between the lower limit and upper limit of the assay range was >500-fold for all serotypes, and assay variability was <20% relative standard deviation (RSD) for all serotypes. IgG antibody measurements were shown to be serotype-specific (some cross-reactivity was observed only between the structurally related serotypes 6A and 6B as well as 19A and 19F), and no interference was observed between the serotypes when the assay was performed in the 13-plex format compared to the singleplex assays. The 13-plex dLIA platform developed by Pfizer Inc. generates up to 143 test results in a single 96-well plate and is a suitable replacement of the enzyme-linked immunosorbent assay (ELISA) platform for evaluating vaccine clinical trials. IMPORTANCE The pneumococcal enzyme-linked immunosorbent assay (ELISA) measures IgG antibodies in human serum, and it is an important assay that supports licensure of pneumococcal vaccines. The immune correlate of protection, 0.35 µg/ml of IgG antibodies, was determined by the ELISA method. Pfizer has developed a new Luminex-based assay platform to replace the ELISA. These papers describe the important work of (i) validating the Luminex-based assay and (ii) bridging the immune correlate of protection (0.35 µg/ml IgG) to equivalent values reported by the Luminex platform.

scholarly journals Mechanisms of Rhinovirus Neutralisation by Antibodies

Viruses ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 360
Author(s):  
Lila Touabi ◽  
Faryal Aflatouni ◽  
Gary R. McLean
Keyword(s):  
Vaccine Development ◽  
Vaccine Design ◽  
Antibody Binding ◽  
Antibody Detection ◽  
Neutralising Antibodies ◽  
Correlate Of Protection ◽  
Immune Correlate ◽  
Aggregation Inhibition ◽  
Icosahedral Capsid

Antibodies are a critical immune correlate of protection for rhinoviruses, particularly those antibodies found in the secretory compartment. For nonenveloped viruses such as rhinoviruses, antibody binding to regions of the icosahedral capsid can neutralise infections by a number of different mechanisms. The purpose of this review is to address the neutralising mechanisms of antibodies to rhinoviruses that would help progress vaccine development. At least five mechanisms of antibody neutralisation have been identified which depend to some extent on the antibody binding footprints upon the capsid. The most studied mechanisms are virion aggregation, inhibition of attachment to cells, and stabilisation or destabilisation of the capsid structure. Newer mechanisms of degradation inside the cell through cytoplasmic antibody detection or outside by phagocytosis rely on what might have been previously considered as non-neutralising antibodies. We discuss these various approaches of antibody interference of rhinoviruses and offer suggestions as to how these could influence vaccine design.

scholarly journals Intralaboratory evaluation of luminescence based high-throughput Serum Bactericidal Assay (L-SBA) to determine bactericidal activity of human sera against Shigella

2020 ◽  
Author(s):  
O. Rossi ◽  
E. Molesti ◽  
A. Saul ◽  
C. Giannelli ◽  
F. Micoli ◽  
...  
Keyword(s):  
Antimicrobial Resistance ◽  
High Throughput ◽  
Bactericidal Activity ◽  
High Specificity ◽  
Effective Vaccine ◽  
Correlate Of Protection ◽  
Bactericidal Assay ◽  
Immune Correlate ◽  
Human Sera ◽  
Serum Bactericidal Assay

ABSTRACTDespite the huge decrease in deaths caused by Shigella worldwide in the last decades, shigellosis is still causing over 200,000 deaths every year. No vaccine is currently available, and the morbidity of disease coupled with the rise of antimicrobial resistance renders the introduction of an effective vaccine extremely urgent. Although a clear immune correlate of protection against shigellosis has not been established yet, the demonstration of bactericidal activity of antibodies induced upon vaccination may provide one means of functionality of antibodies induced on protecting against Shigella. The method of choice to evaluate the complement-mediated functional activity of vaccine-induced antibodies is the Serum Bactericidal Assay (SBA).Here we present the development and intra-laboratory characterisation of a high-throughput luminescence-based SBA (L-SBA) method, based on the detection of ATP as a proxy of surviving bacteria, to evaluate the complement-mediated killing of human sera. We demonstrated the high specificity of the assay against homologous strain without any heterologous aspecificity detected against species-related and not species-related strains. We assessed linearity, repeatability and reproducibility of L-SBA on human sera.This work will guide the bactericidal activity assessment of clinical sera raised against S. sonnei. The method has the potential of being applicable with similar performances to determine bactericidal activity of any non-clinical and clinical sera that rely on complement mediated killing.IMPORTANCEShigella is an important cause of diarrhoea worldwide and antimicrobial resistance is on rise, thus efforts by several groups are ongoing to produce a safe and effective vaccine against shigellosis. Although a clear immune correlate of protection has not been established, demonstration of bactericidal capacity of sera from patients immunised with Shigella vaccines may provide one means of protecting against shigellosis. We have developed and fully characterised a novel high-throughput L-SBA method for evaluation of functionality of antibodies raised against S. sonnei in human sera. This work will allow the clinical testing of human sera raised against GMMA-based and potentially all vaccines producing antibodies than can work via complement mediated manner.

The quest for a T cell-based immune correlate of protection against HIV: a story of trials and errors

2010 ◽  
Vol 11 (1) ◽  
pp. 65-70 ◽  
Author(s):  
Richard A. Koup ◽  
Barney S. Graham ◽  
Daniel C. Douek
Keyword(s):  
T Cell ◽  
Correlate Of Protection ◽  
Immune Correlate

scholarly journals Rapid and Durable Protection Against Marburg Virus with a Single-Shot ChAd3-MARV GP Vaccine

2021 ◽  
Author(s):  
Ruth Hunegnaw ◽  
Anna Honko ◽  
Lingshu Wang ◽  
Derick Carr ◽  
Tamar Murray ◽  
...  
Keyword(s):  
Adenovirus Vector ◽  
Hemorrhagic Fever ◽  
Marburg Virus ◽  
Single Shot ◽  
Lethal Challenge ◽  
Post Vaccination ◽  
Correlate Of Protection ◽  
Immune Correlate ◽  
First Case ◽  
One Year

Marburg virus (MARV) causes a severe hemorrhagic fever disease in primates with mortality rates in humans up to 90%. Since 2018, MARV has been identified as a priority pathogen by the WHO, needing urgent research and development of countermeasures due to the high public health risk it poses. Recently, the first case of MARV in West Africa underscored the significant outbreak potential of this virus. The potential for cross border spread as had occurred during the Ebola 2014-2016 outbreak illustrates the critical need for Marburg vaccines. To support regulatory approval of the ChAd3-Marburg vaccine that has completed Phase I trials, we show that a non-replicating chimpanzee-derived adenovirus vector with a demonstrated safety profile in humans (ChAd3) protected against a uniformly lethal challenge with Marburg-Angola. Protective immunity was achieved within 7 days of vaccination and was maintained through one year post vaccination, antigen-specific antibodies were a significant immune correlate of protection in the acute challenge model (p=0.0003), and predictive for protection with an AUC = 0.88. These results demonstrate that a single-shot ChAd3 MARV vaccine generated a protective immune response that was both rapid and durable with a significant immune correlate of protection that will support advanced clinical development.

in vivo anthelmintic activity of Syzygium cumini leaves against Haemonchus contortus in sheep

Planta Medica ◽  
2012 ◽  
Vol 78 (11) ◽  
Author(s):  
LDR Oliveira ◽  
JPHV Miranda ◽  
GS Curado ◽  
JP Costa Neto ◽  
BF Santos ◽  
...  
Keyword(s):  
Haemonchus Contortus ◽  
Anthelmintic Activity ◽  
Syzygium Cumini

Haemonchus contortus: in vivo anthelmintic activity of leaves of anacardium humile

Planta Medica ◽  
2012 ◽  
Vol 78 (11) ◽  
Author(s):  
LDR Oliveira ◽  
JPHV Miranda ◽  
GS Curado ◽  
JP Costa Neto ◽  
BF Santos ◽  
...  
Keyword(s):  
Haemonchus Contortus ◽  
Anthelmintic Activity

Effect of Jatropha curcas Latex on L3 Haemonchus contortus Larval Motility

2017 ◽  
Vol 9 (3) ◽  
Author(s):  
Noorzaid Muhamad ◽  
Syahirah Sazeli ◽  
Resni Mona ◽  
Jannathul Firdous
Keyword(s):  
Larvicidal Activity ◽  
Jatropha Curcas ◽  
Haemonchus Contortus ◽  
Anthelmintic Resistance ◽  
Small Ruminants ◽  
Gastrointestinal Nematodes ◽  
Dose Dependent ◽  
Plants Extract

The anthelmintic resistance has limited the control of gastrointestinal nematodes of small ruminants and thus has awakened interest in the study of plants extract as a source of anthelmintics. These experiments were carried out to evaluate the in vitro efficacy of Jatrophacurcas latex extract against Haemonchuscontortus larval motility. To evaluate the larvicidal activity, H.contortus L3 were incubated with the extracts with varying concentration of 5 mg/mL, 10 mg/mL, 15 mg/mL and 20 mg/mL at 27°C for 48, 72 and 96 hrs. The results were subjected to the Kruskal-Wallis test (P less than 0.05). The extracts showed dose-dependent larvicidal effects. These results suggest that J.curcas can be used to control gastrointestinal nematodes of small ruminants.

Sign in / Sign up

Export Citation Format

Share Document